Back to today’s briefing

Story perspectives

Medicare Drug Price Cuts Threatened by PBM Tactics

6/6/2025

27 3

Summary

Story summary

The Inflation Reduction Act seeks to cut Medicare drug prices through government negotiations, but Pharmacy Benefit Managers (PBMs) might counteract these savings by reclassifying medications. This maneuver could burden patients with an extra $482 million for Apixaban and $206 million for Rivaroxaban, jeopardizing access to vital treatments for over 320,000 individuals.

1 of 1

Story summary

The Inflation Reduction Act seeks to cut Medicare drug prices through government negotiations, but Pharmacy Benefit Managers (PBMs) might counteract these savings by reclassifying medications. This maneuver could burden patients with an extra $482 million for Apixaban and $206 million for Rivaroxaban, jeopardizing access to vital treatments for over 320,000 individuals.